• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

by MM360 Staff | Dec 9, 2025 | Publications

Cureus. 2025 Dec 3;17(12):e98368. doi: 10.7759/cureus.98368. eCollection 2025 Dec. ABSTRACT Relapsed/refractory multiple myeloma (RRMM) remains a challenging condition with a need for more effective treatment options. There are ongoing clinical trials analyzing the...

by MM360 Staff | Dec 9, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

by MM360 Staff | Dec 9, 2025 | Uncategorized

Source: CURE articles Post Content Read More

CLN-049 now has FDA fast track designation for hard-to-treat AML

by Marisa Wexler, MS | Dec 8, 2025 | Myeloma News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the experimental medicine FCLN-049, which is being developed as a potential treatment for relapsed or refractory acute myeloid leukemia (AML). This designation aims to expedite the...

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

by MM360 Staff | Dec 8, 2025 | Publications

Blood Cancer J. 2025 Dec 6;15(1):212. doi: 10.1038/s41408-025-01413-7. ABSTRACT Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet...
« Older Entries
Next Entries »

Recent Content

  • Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • (no title)
  • Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
  • CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT